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Abstract The objective of the study was to measure patient
attitudes and experience of information received during drug
counselling for rheumatoid arthritis (RA) medications. This is
a cross-sectional UK postal questionnaire study. Three RA
patient groups—disease-modifying antirheumatic drugs
(DMARDs) only, first anti-tumour necrosis factor (anti-
TNF) and failed anti-TNF—were sent postal questionnaires.
Data on patient history/demographics, drug counselling expe-
rience, knowledge of drug side effects, attitudes to vaccina-
tions, cancer screening and blood borne virus testing was col-
lected; 264/679 (39%) patients responded (median age
65 years, 66% female, median disease duration 15 years).
Drug information from rheumatology nurses, rheumatology
doctors and information leaflets was most useful. Thirty-
eight percent of respondents felt reassured by information re-
ceived, but 37% felt more worried. Forty percent of partici-
pants were aware of important drug side effects. Although 42–
65% of patients understood they should temporarily halt anti-
TNF therapy with concurrent infection, 75% of patients
recalled continuing therapy despite infection. Thirteen percent
believed that all vaccinations (including travel vaccinations)
were safe while taking anti-TNF. Uptake of UK cancer screen-
ing programmes was between 87 and 94%, except prostate
screening (47%). Most participants were not aware that they
may need to discontinue their anti-TNF if they developed
cancer. The majority of participants felt neutral/reassured by
the prospect of viral hepatitis (95%) and HIV (91%) testing.
Although drug counselling is a well-established part of clini-
cal care, there is potential for further improvement to ensure
that patients’ knowledge empowers them to act safely.
Particular areas for improvement included the following: pa-
tients halting DMARDs/anti-TNF therapy during infections,
knowledge regarding vaccinations and prostate cancer screen-
ing uptake.
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Introduction
Patient education has an important role in the management of
rheumatoid arthritis (RA). Patient education programmes can
benefit patient’s disease knowledge and disease activity [1, 2].
Many rheumatology centres have both disease and medication
educational programmes, with information from various
sources (physicians, allied health professionals, patient sup-
port groups, other patients, family, internet/media) [3].
Increasingly, counselling is being provided by community-
based health professionals, rather than hospital staff. Despite
participation in drug counselling, patients often lack key
knowledge about their disease/medication [4, 5].
Qualitative studies exploring attitudes towards RA patient
education and drug counselling [6–11] identify high patient
expectations of information provision, with general satisfac-
tion regarding quality and timing; however, quantitative data
are lacking. Increasing numbers of RA patients receive paren-
teral therapies [12, 13], with potentially serious side effects,
posing new challenges in RA patient education [14, 15].
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This is the first quantitative study, describing knowledge
and attitudes about RA therapies from the patients’ perspec-
tive in the UK. Data has been particularly lacking on issues
such as knowledge and uptake of vaccinations, cancer screen-
ing and acceptability of testing for blood-borne viruses. This
study measured patient attitudes and experience of informa-
tion received while starting immunosuppressive medications,
with a particular focus on anti-TNF medications.
Methods
This cross-sectional postal questionnaire study was conducted
across a population of 807,000, 96% white Caucasians in
Staffordshire, UK, requiring specialist rheumatology care for
5000+ RA patients, with over 1000 patients having received at
least one biological agent. Ethical approval was obtained from
the Staffordshire Local Research Ethics Committees. Written
consent was obtained according to the Declaration of
Helsinki.
Patients starting new therapy receive face-to-face drug
counselling from a specialist nurse and written information
on treatment and potential side effects. Those starting biologic
therapy are assessed for malignancy and are screened for tu-
berculosis/hepatitis. Six hundred seventy-nine prospective
participants were sampled from three existing lists of RA pa-
tients, using random number generation: group I: patients tak-
ing their first anti-TNF agent, group II: patients who had failed
their first anti-TNF agent and group III: patients taking
disease-modifying antirheumatic drugs (DMARDs) without
exposure to biologic agents.
Data were collected by self-administered postal question-
naires, developed from a previous study [6] including patient
history/demographics, drug counselling experience, knowl-
edge of drug side effects and attitudes to vaccinations, cancer
screening and blood-borne virus testing. Patient global assess-
ment [16, 17] was used as an indication of RA disease impact
and index of multiple deprivation based on postcode [18] -
measured socioeconomic status.
Data were analysed with simple descriptive statistics:
mean/standard deviation for continuous data and counts/
proportions for categorical data. Associations between partic-
ipant variables and responses used chi-square (two categorical
variables), unpaired t (one categorical and one continuous
variable) and Pearson correlation (two continuous variables)
tests.
Knowledge about drug side effects were classified as in-
correct if the anti-TNF groups did not recognise that anti-TNF
could cause a rash, increased risk of infection and theoretical
increased risk from cancer. DMARD participant responses
were classified as correct if they recognised common potential
side effects of DMARDS including rash, high blood pressure
(leflunomide), abnormal liver blood tests (methotrexate,
sulphasalazine and azathioprine), abnormal kidney blood tests
(gold) and increased risk of infection (methotrexate and
azathioprine).
Participants were only included in cancer screening analy-
sis if they were eligible for screening based on age/gender
[19–21]: bowel cancer screening participants aged 60–
69 years, breast cancer (mammography) for women aged
50–70 years, cervical cancer (smear) for women aged 25–
64 years, and prostate cancer (prostate-specific antigen
(PSA)) for men aged over 50 years.
Results
264/679 (39%) patients responded, with similar rates between
patient groups. Sixty-six percent were female with median
(IQR) age 65 (55–71) years, median (IQR) years since diag-
nosis 15 (8–25), and mean (SD) patient global assessment
(PGA) 43 (27)/100. Demographic and clinical details for each
patient group are shown in Table 1.
The most common information sources about prospective
medications were rheumatology nurses (94%), rheumatology
doctors (90%) and information leaflets (84%). Patients re-
ceived information from internet/website, general practitioner,
newspaper/TV, general practice nurse, other patients and
friends/family less frequently. Information from rheumatology
nurses, rheumatology doctors and information leaflets were
found most useful. Internet/website information was signifi-
cantly more useful in younger participants (p = 0.009).
Patients with the longest disease duration found information
from GP nurses (p = 0.011) and friends/family (p = 0.019)
least useful. Participants in the failed anti-TNF group found
information from general practitioner less useful (p = 0.006).
Participants were generally satisfied with the information
received. Ninety-one percent said they received ‘almost
enough’, ‘just right’ or ‘a bit too much’ information; 92% said
the quality was ‘acceptable’, ‘good’ or ‘very good’; and 97%
said the timing was ‘a bit too early’, ‘about right’ or ‘a bit too
late’. When asked about how much information they had al-
ready known, 95% responded ‘none’, ‘a little’ or ‘some’.
These responses varied little between verbal and written
information.
Thirty-eight percent of respondents felt reassured/slightly
reassured by information they received, 22% felt neutral, but
37% reported feeling more worried/slightly worried. The first
anti-TNF group reported significantly greater reassurance than
the other participants (p = 0.012).
Participants reported that rheumatology nurses were the
easiest to ask when seeking further information, followed by
rheumatology doctors and then hospital pharmacists. Health
professionals in community settings (GPs, practice nurses,
pharmacists) were felt less easy to ask, particularly for those
with longer disease duration (p = 0.049, p = 0.002 and
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p = 0.019, respectively). Socioeconomic status had no appar-
ent effect on information gathering from any source.
Exploring knowledge of common anti-TNF or DMARD
side effects (Table 2), 40% of participants were aware of all
important applicable side effects. Although, this was highest
for the DMARD group (57%), excluding ‘theoretical in-
creased risk from cancer’ from analysis, the anti-TNF groups
performed at a similar level (55 and 62%, respectively).
Participants’ concerns on starting new treatments were the
highest with increased risk from cancer, increased infections
and deteriorating mood. Older participants were reluctant to
start medication potentially causing rashes (p ≤ 0.005) or lim-
iting travel vaccinations (p = 0.007). DMARD patients were
more reluctant to start medications across all potential side
effect areas. The first anti-TNF patients were less concerned
starting a medication potentially causing rashes (p = 0.049).
The failed anti-TNF patients were less concerned about po-
tential increased risk from cancer (p = 0.037). Female partic-
ipants were more likely to continue medication with potential
to increase risk from cancer (p = 0.038) or worsen mood
(p = 0.033).
Participants were asked if anti-TNF/DMARD medication
should be temporarily withheld if they experienced different
symptoms/infections. They reported treatment cessation with
chest infections (65%), vomiting (45%), urine infections
(42%) and skin infections (42%). The failed anti-TNF group
were most likely to believe medication should be withheld.
Participants were asked whether they had actually stopped
their medication during infections. Medication was continued
in 778/1040 infective episodes (75%) despite patients believ-
ing they should have stopped in 139 of these cases (18%).
Appropriate cessation occurred less in DMARD (31%) than
that in the first anti-TNF (84%) and failed anti-TNF (78%)
groups.
Attitudes, uptake and knowledge about vaccinations [22,
23] are shown in Table 3. Most participants (93%) felt annual
influenza immunisation were important, with 76% of respon-
dents being immunised annually. Seventeen percent were
aware that influenza immunisation was important but only
received it ‘some years’ or ‘never’. Amongst the anti-TNF
groups, 13% believed that all vaccinations (including travel
vaccinations) were safe while taking anti-TNF.







Female n (%) 64 (66) 61 (72) 49 (61)
Median (IQR) age 64 (52–72) 65 (56–71) 65 (57–72)
Patient global assessment—VAS score, mm (SD) 39 (24) 53 (28) 39 (28)
Infliximab n (%) 23 (26) 23 (35) –
Etanercept n (%) 24 (27) 17 (26) –
Adalimumab n (%) 31 (35) 21 (32) –
Certolizumab n (%) 11 (12) 4 (6) –
Single therapy n (%) – – 44 (55)
Dual therapy n (%) – – 27 (34)
Triple therapy n (%) – – 9 (11)
Methotrexate n (%) – – 60 (75)
Sulphasalazine n (%) – – 27 (34)
Leflunomide n (%) – – 11 (14)
Hydroxychloroquine n (%) – – 23 (29)
Azathioprine n (%) – – 3 (4)
Other n (%) – 1 (1)
Currently on alternative anti-TNF n (%) 28 (43)
Currently on other biologic agent n (%) 31 (48)
Number of previously failed DMARDs n (%)
0 8 (9) 7 (11) 39 (49)
1 27 (30) 15 (23) 24 (30)
2 26 (29) 10 (15) 8 (10)
3 15 (17) 14 (22) 6 (7)
>3 13 (15) 19 (29) 3 (4)
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Attitudes, uptake and knowledge about cancer screening
are shown in Table 4. Seventy-nine percent of participants
believed that involvement in cancer screening programmes
was important. Overall uptake of those eligible for cancer
screening programmes were bowel cancer (stool sample)
89%, breast cancer (mammography) 94%, cervical cancer
(smear) 87% and prostate cancer (PSA measurement) 43%.
These proportions did not vary significantly with the patient
group.
Most participants reported feeling neutral/reassured by vi-
ral hepatitis (95%) and HIV (91%) testing. Most would agree
to viral hepatitis (92%) or HIV (81%) testing. Younger partic-
ipants were less concerned by the prospect of both tests
(p = 0.043 and p ≤ 0.005), and more likely to agree to testing
(p = 0.018 and p ≤ 0.005), as were male participants
(p ≤ 0.005).
Discussion
Study limitations include a moderate response rate (39%) af-
fecting overall respondent numbers. Participants were pre-
dominantly white Caucasians, potentially limiting applicabil-
ity of findings in other patient populations.
Participants found specialist sources (rheumatology nurses
and doctors and information leaflets) most useful as additional
information sources, particularly those initiating biologic ther-
apies. Participants with longer disease duration found infor-
mation from their friends/family and community nurses less
useful, possibly indicating a preference for specialist rheuma-
tology involvement. The DMARD group found information
from rheumatology nurse teams less useful, in contrast to the
anti-TNF group, who had closer monitoring with the dedicat-
ed rheumatology nurses. This highlights the need for identi-
fied case workers and a single point of contact regarding pa-
tient education.
Knowledge levels prior to medication counselling was
poor, confirming patients’ need for education. Although par-
ticipants highly rated the amount, quality and timing of infor-
mation they received, education actually increased concern in
similar numbers to those reporting reassurance. Different pa-
tients clearly require different levels of information when con-
sidering new medications, highlighting the importance of a
patient-centred approach [24]. The first anti-TNF group par-
ticipants were significantly more reassured than the anti-TNF
failure group, who possibly have their viewpoint skewed by
previous negative experiences.
Rheumatology nurses were preferential sources of informa-
tion over other health professionals, supporting the integral




















man in the street’
(N = 94) (N = 83) (N = 77)
Much less important 3 3 3 9
A bit less important 1 1 6 8
The same 7 4 8 19
A bit more important 13 13 15 41
Much more important 70 62 45 177
Reported uptake of flu
jab
(N = 95) (N = 84) (N = 79)
Never 16 13 17 46
Some years 8 6 2 16
Every year 71 65 60 196








(N = 95) (N = 84) (N = 80)
Safe 14 9 14 37
Not safe 25 37 21 83
Unsure 56 38 45 139
Table 2 Knowledge of drug side effects by patent group
Proportion who correctly identified that anti-TNF (first
and failed anti-TNF groups) or participants’ current
DMARDs (DMARD group) could cause different side
effects












Skin rash 56/97 (58) 57/86 (66) 14/24 (58) 127/ 207 (61)
Abnormal liver
blood tests




– – 0/1 (0) 0/1 (0)
High blood
pressure
– – 8/11 (73) 8/11 (73)
Increased risk of
infections




41/97 (42) 38/86 (44) – 79/183 (43)
All correct 30/97 (31) 29/86 (34) 46/81 (57) 105/264 (40)
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role specialist nurses play in the rheumatology multidisciplin-
ary team. There was also preference for other hospital special-
ists, particularly pronounced amongst patients on anti-TNF
and with longer disease durations. This could represent in-
creased patient dependency on specialist care, or that commu-
nity health professionals are less comfortable providing opin-
ions on more complex patients. The TNF groups reported
easier access to specialists (particularly rheumatology doc-
tors), probably due to closer specialist supervision.
Participant knowledge of drug adverse effects was lower
than expected, with poor identification of side effects com-
monly associated with DMARDs/anti-TNF. This may be
due to poor information recall, but still represents a short-
fall in patient knowledge [4]. Participants in the anti-TNF
groups were more accepting of potential side effects (in-
cluding infections and risk from cancer). Possibly, patients
with more severe disease accept higher risks to achieve
symptomatic control [6]. Older participants were more
accepting of potential cancer risks, but more concerned
around risks of developing/worsening depression.
Attitudes towards temporarily withholding medications
despite concurrent symptoms/infections varied depending
on medication group. DMARD patients believed less of-
ten that medications should be stopped. It is concerning
that the majority of patients did not withhold medications
in presence of symptoms/infections, including those who
were aware that they should. Although adherence was
better in anti-TNF patients, the clinical risk is potentially
considerable.
Vaccination knowledge was encouraging with vaccination
uptake generally high, and most participants aware that annual
influenza immunisation was important. Amongst the minority
not receiving annual influenza immunisations, most still per-
ceived it to be important. This discrepancy could relate to
difficulty accessing immunisations or fear of injection/side
effects. Although only a minority of respondents believed that
all vaccinations were safe while taking anti-TNF, this group is
important to identify as they could be at significant clinical
risk, particularly if vaccination providers are unaware of RA
medications (particularly hospital prescribed parenteral
therapies).
Uptake of UK national cancer screening was good,
with the exception of prostate cancer testing (no national
register, patients not routinely invited to participate).
Cancer screening is arguably particularly important for
patients on anti-TNF medications, stopping these medi-
cations early should cancer develop potentially improv-
ing patient outcome. Current clinical practice could be
improved if encouragement to engage with all cancer
screening programmes was included in anti-TNF guide-
lines, particularly as most participants were unaware that
anti-TNF would be stopped should they develop cancer.
There are high levels of patient acceptability for viral
hepatitis and HIV testing, supporting the concept of in-
creased testing advocated in other specialist settings [25].
Even in low HIV-prevalence populations, we would sug-
gest including these tests for all prospective anti-TNF
patients.
Table 4 Attitudes, uptake and knowledge about cancer screening
First anti-TNF group n (%) Anti-TNF failure group n (%) DMARD group n (%) All participants n (%)
Perceived importance of cancer screening for patients
with RA taking anti-TNF/DMARDs compared
with ‘the man in the street’
(N = 94) (N = 82) (N = 76) (N = 252)
Much less important 0 (0) 0 (0) 0 (0) 0 (0)
A bit less important 20 (21) 12 (15) 20 (26) 52 (21)
The same 33 (35) 21 (26) 27 (36) 81 (32)
A bit more important 41 (44) 49 (60) 29 (38) 119 (47)
Much more important 0 (0) 0 (0) 0 (0) 0 (0)
Reported use of national cancer screening programmes
(only individuals eligible based on age/gender
included)
Bowel cancer (stool sample) 22/27 (81) 24/28 (86) 24/24 (100) 70/79 (89)
Breast cancer (mammogram) 33/36 (92) 38/40 (95) 27/28 (96) 98/104 (94)
Cervical cancer (smear) 29/36 (81) 24/27 (89) 24/26 (92) 77/89 (87)
Prostate cancer (PSA) 12/25 (46) 7/21 (33) 11/24 (46) 30/70 (43)
Perceived need for anti-TNF/DMARD medication
to be stopped if developed cancer
(N = 94) (N = 84) (N = 79) (N = 257)
Never 4 (4) 2 (2) 2 (2) 8 (3)
Occasionally 0 (0) 2 (2) 1 (1) 3 (1)
Sometimes 6 (6) 7 (7) 8 (10) 21 (8)
Usually 9 (10) 12 (13) 1 (1) 22 (9)
Always 19 (20) 23 (27) 4 (5) 46 (18)
Do not know 56 (60) 38 (45) 63 (80) 157 (61)
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Summary
Although drug counselling is a well-established part of clini-
cal care, there is potential for further improvement to ensure
that patients’ knowledge empowers them to act safely and
appropriately. Current levels of patient education still result
in potentially avoidable risks around vaccination, cancer
screening and drug cessation for infection. Education by the
rheumatology team, particularly specialist nurses, is highly
valued by the majority of patients, particularly those with
more complex disease.
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Key messages
1. There is potential to improve drug counselling to ensure that
patients act safely and appropriately.
2. Improved patient education could reduce risks around vaccination,
cancer screening and infection-related drug cessation.
3. Rheumatology nurse education is highly valued by patients,
particularly those with complex disease.
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